Oncolytic viruses in cancer therapy

European Journal of Scientific Research

Volumn 40, Issue 1, 2010, Pages 156-171

  Meerani, Saleem ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cancer; Clinical trials; Gene therapy; Metastatic tumors; Oncolytic viruses

Indexed keywords

EID: 78650537687     PISSN: 1450216X     EISSN: 1450202X     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Elizabeth Kelly and Stephen J Russell: History of Oncolytic Viruses: Genesis to Genetic Engineering.
2. John T, Mullen and Kenneth K, Tanabe: Viral Oncolysis, the Oncologist 7:106-119, 2002;
3. Tollefson AE, Ryerse JS, Scaria A et al: The E3-11.6 kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 220:152-162.
4. Shtrichman R and Kleinberger T: Adenovirus type 5 E4 open reading frame 4 protein induces apoptosis in transformed cells. J Virol; 72:2975-2982. 1998; (Pubitemid 28175536)
5. Gooding LR: Regulation of TNF-mediated cell death and inflammation by human adenoviruses. Infect Agents Dis; 3:106-115, 1994 (Pubitemid 24280989)
6. Toda M, Rabkin SD, Kojima H et al: Herpes simplex virus as an in situ cancer vaccine for the induction of specific antitumor immunity. Human Gene Therapy; 10:385-393, 1999 (Pubitemid 29097317)
7. Steve H Thorne and David H Kim: Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus.
8. Daniel Cervantes-Garcia, Rocio Ortiz-Lopez, Netzahualcoyotl Mayek-Perez and Augusto Rojas-Martinez: Oncolytic Virotherapy, Annals of Hepatology 7(1): January-March: 34-45, 2008;
9. Martuza RL, Malick A, Markert JM, et al: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science; 252:854-856, 1991 (Pubitemid 121000529)
10. Susan Varghese and Samuel D Rabkin: Oncolytic herpes simplex virus vectors for cancer virotherapy, Cancer Gene Therapy, 9, 967-978, (2002) (Pubitemid 35462560)
11. Mellerick DM and Fraser NW: Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state. Virology. 158:265-275, 1987 (Pubitemid 17083353)
12. Deanna Cross and James K. Burmester: Gene Therapy for Cancer Treatment: Past, Present and Future Clinical Medicine & Research, Volume 4, Number 3:218-227.
13. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A and McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science; 274:373-376, 1996 (Pubitemid 26353341)
14. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, and Kirn D: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res; 60:6359-6366, 2000
15. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA and McCarty TM: A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol; 7:588-592, 2000
16. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S Jr, Recant W, El-Naggar AK, Stenson K, Lippman SM, Hong WK and Vokes EE: An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol; 21:4546-4552, 2003. (Pubitemid 46594025)
17. Rodriguez R, Sachuur ER, Lim HY et al: Prostate attenuated replication competent adenovirus (ARCA) CV706: a selectively cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res; 57:2559-2563, 1997 (Pubitemid 27283756)
18. Wallack MK, Sivanandham M, Balch CM et al: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg; 187:69-77, 1998.
19. Bischoff JR, Kirn DH, Williams A et al: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science; 274:373-376, 1996. (Pubitemid 26353341)
20. Rogulski KR, Freytag SO, Zhang K et al: In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res; 60:1193-1196, 2000. (Pubitemid 30151981)
21. Cassel WA, Murray DR and Phillips HS: A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer; 52:856-860, 1983. (Pubitemid 13037651)
22. Livingston PO, Albino AP, Chung TJ et al: Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer; 55:713-720, 1985. (Pubitemid 15173507)
23. Markert JM, Medlock MD, Rabkin SD, et al: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther.; 7:867-874, 2000 (Pubitemid 30303584)
24. Rampling R, Cruickshank G, Papanastassiou V, et al: Toxicity evaluation of replicationcompetent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther.; 7:859-866, 2000. (Pubitemid 30303583)
25. Papanastassiou V, Rampling R, Fraser M, et al: The potential for efficacy of the modified ICP 34.5-herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther.; 9:398-406, 2002. (Pubitemid 34414038)
26. MacKie RM, Stewart B and Brown SM: Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet. 357:525-526, 2001. (Pubitemid 32173591)
27. Fong Y, Kemeny N, Jarnagin W, et al: Phase 1 study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases. Am Soc Clin Oncol Ann Meeting. 2002:27.
28. Yu D, Chen Y, Seng M et al: The addition of adenovirus type 5 region E3 enables Calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 59:4200-4203, 1999. (Pubitemid 29418725)
29. Kurihara T, Brough DE, Kovesdi I et al: Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 106:763-771, 2000.
30. Miyatake S-I, Tani S, Feigenbaum F et al: Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther 6:564-572, 1999. (Pubitemid 29192665)
31. Strong JE and Lee PW: The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 70:612-616, 1996. (Pubitemid 126508834)
32. Coffey MC, Strong JE, Forsyth PA et al: Reovirus therapy of tumors with activated Ras pathway. Science 282:1332-1334, 1998. (Pubitemid 28524498)
33. Hirasawa K, Yoon C, Nishikawa SG et al: Reovirus therapy of metastatic cancer models in immune-competent mice. Proc Am Assoc Cancer Res; 42:2437a, 2001.
34. Whyte P, Buchkovich KJ, Horowitz JM et al: Association between an oncogene and an antioncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature; 334:124-129, 1988.
35. Yew PR and Berk AJ: Inhibition of p53 transactivation required for transformation by adenovirus early E1B protein. Nature 357:82-85, 1992.
36. Heise C, Ganly I, Kim YT et al: Efficacy of a replicationselective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther 7:1925-1929, 2000.
37. Habib NA, Sarraf CE, Mitry RR et al: E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 12:219-226, 2001. (Pubitemid 32163894)
38. Rodriguez R, Schuur ER, Lim HY et al: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57:2559-2563, 1997. (Pubitemid 27283756)
39. Cozzi PJ, Malhotra S, McAuliffe P, Kooby DA, Federoff HJ, Huryk B, Johnson P, Scardino PT, Heston WD and Fong Y: Intravesical oncolytic viral therapy using attenuated, replicationcompetent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J; 15:1306-1308, 2001.
40. Liu R, Varghese S and Rabkin SD: Oncolytic herpes simplex virus vector therapy of breast cancer in C3 (1)/SV40 T-antigen transgenic mice. Cancer Res; 65:1532-1540, 2005. (Pubitemid 40270182)
41. Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J, Petrowsky H, Mastorides S, Federoff H and Fong Y: Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther; 9:935-945, 2002. (Pubitemid 35278566)
42. McAuliffe PF, Jarnagin WR, Johnson P, Delman KA, Federoff H and Fong Y: Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg; 4:580-588, 2000.
43. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F and Martuza RL: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther; 7:867-874, 2000. (Pubitemid 30303584)
44. Information on clinical trials and human research studies: ClinicalTrials.gov Web site. Available at: http://www.clinicaltrials.gov/. Accessed July 31, 2006.
45. Optim OncoVEXGM-CSF Phase III trial in Melanoma: www. Biovex.com Nov:2009.
46. K. Harrington, M. Hingorani, M. Tanay, J. Matthews, K. Newbold, L. Renouf, H. Goldsweig, I. McNeish, R. S. Coffin, C. Nutting: A phase I/II dose escalation study of OncoVexGM-CSF and chemoradiotherapy in untreated stage III/IV squamous cell cancer of the head and neck. American Society of Clinical Oncology (ASCO) Annual Meeting, 1 June 2009.
47. Still, GF: On a form of chronic joint disease in children. Med Chir Soc 80:52. (1897).
48. Hoster, H, Zanes R and vonHaam E: The association of "viral" hepatitis and Hodgkin's disease. Cancer Res 9:473-480, AE (1949).
49. Southam CM, and Moore: Clinical studies of viruses as antineoplastic agents, with particular reference to Egypt 101 virus. Cancer 5:1025-1034, AE (1952)
50. Moore: The destructive effects of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer 2:525-534, AE (1949).
51. Moore: Effects of viruses on tumors. Annu Rev Microbiol 8:393-410, AE (1954).
52. Moore: Inhibition of growth of five transplantable mouse tumours by the virus of Russian far east encephalitis. Cancer 4:375-382, AE (1951).
53. Moore: Viruses with oncolytic properties and their adaptation in tumours. Ann N Y Acad Sci USA 54:945-952, AE (1952).
54. Southam, CM and Moore: West Nile, Ilheus, and Bunyamwera virus infections in man. Am J Trop Med Hyg 31:724-741, AE (1951).
55. Mettler, NE, Clarke, DH and Casals, J: Virus inoculation in mice bearing Ehrlich ascitic tumors: antigen production and tumor regression. Infect Immun 37:23-27, 1982. (Pubitemid 12095176)
56. Webb, HE, Wetherley-Mein, G, Smith, CE and McMahon, D: Leukaemia and neoplastic processes treated with Langat and Kyasanur Forest disease viruses: a clinical and laboratory study of 28 patients. Br Med J 1:258-266, 1966.
57. Huebner, RJ, Bell, JA, Rowe, WP, Ward, TG, Suskind, RG, Hartley, JW et al: Studies of adenoidal-pharyngeal-conjunctival vaccines in volunteers. J Am Med Assoc 159:986-989, (1955).
58. Pack: Note of the experimental use of rabies vaccine for melanomatosis. Arch Dermatol 62:694-695, GT (1950).
59. Milton, GW and Brown: The limited role of attenuated smallpox virus in the management of advanced malignant melanoma. Aust N Z J Surg 35:286-290, MM (1966).
60. Minton: Mumps virus and BCG vaccine in metastatic melanoma. Arch Surg 106:503-506, JP (1973)
61. Fong Y, Kemeny N, Jarnagin S, Stanziale S, Guilfoyle B, Gusani N et al: Phase 1 study of a replicationcompetent Herpes Simplex oncolytic virus for treatment of hepatic colorectal metastases. Abstract # 27, American Society of Clinical Oncology 38th annual meeting proceedings Vol 2: Part 1, 8a. 2002.
62. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7(10):867-874, 2000. (Pubitemid 30303584)
63. Varghese S and Rabkin SD: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 9(12):967-978, 2002. (Pubitemid 35462560)
64. Brendon M. Stiles, Prasad S Adusumilli, Amit Bhargava, Stephen F. Stanziale, Teresa H. Kim, Mei-Ki Chan, Rumana Huq, Richard Wong, Valerie W. Rusch, and Yuman Fong: Minimally-Invasive Localization of Oncolytic Herpes Simplex Viral Therapy of Metastatic Pleural Cancer. Cancer Gene Ther. 13(1):53-64, 2006. (Pubitemid 41816349)
65. Michael I. Ebright, Jonathan S. Zager, Sandeep Malhotra, Keith A. Delman, Tracey L. Weigel, MD Valerie W. Rusch and Yuman Fong: Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. J Thoracic Cardiovasc Surg 124 (1).
66. James M Markert, Peter G Liechty, Wenquan Wang, Shanna Gaston, Eunice Braz, Matthias Karrasch, Louis B Nabors, Michael Markiewicz, Alfred D Lakeman, Cheryl A Palmer, Jacqueline N Parker, Richard J Whitley and George Y Gillespie: Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM. Molecular Therapy 17(1):199-207, 2009.
67. David A. Kooby, John F. Carew, Marc W. Halterman, Jonathan E. Mack, Joseph R. Bertino, Leslie H. Blumgart, Howard J. Federoff, And Yuman Fong: Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 13:1999.
68. Susan Varghese, Samuel D. Rabkin, G. Petur Nielsen, Usha MacGarvey, Renbin Liu, and Robert L. Martuza: Systemic Therapy of Spontaneous Prostate Cancer in Transgenic Mice with Oncolytic Herpes Simplex Viruses, Cancer Res 67(19):2007.
69. Dr. Mae-Wan Ho: ISIS Press Release 29/03/05
70. J. J. Davis and B. Fang: Oncolytic virotherapy for cancer treatment: challenges and solutions, Gene Med; 7:1380-1389, 2005. (Pubitemid 41672396)
71. Wein LM, Wu JT, and Kirn DH: Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res; 63:1317-1324, 2003. (Pubitemid 36348711)
72. Demers GW, Johnson DE, Tsai V, Wen SF, Quijano E, Machemer T, Philopena J, Ramachandra M, Howe JA, Shabram P, Ralston R and Engler H: Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy. Cancer Res; 63:4003-4008, 2003. (Pubitemid 36917919)
73. Moria Brown: Killer into cure-oncolytic viruses, microbiology today aug 2005.
74. Deanna Cross and James K. Burmester: Gene Therapy for Cancer Treatment: Past, Present and Future, Clinical Medicine & Research 4(3):218-227.